B

Baroness Merron (Lab)

Speaking in the House of Lords on 19 November 2026

Debate

Access to Clinical Trials

Contribution

We work closely with the devolved Administrations so that we can extend this UK-wide. As the noble Baroness will know, the national cancer plan includes a dedicated chapter for action on rare and less common cancers, including how we will make them a research priority and implement this year’s Rare Cancers Act to give more patients access to clinical trials in respect of rare cancers. There are two complementary roles: we have Dr Metcalf driving clinical improvement and delivery through the national cancer board, as the national cancer lead, but we also have Dr Stoneham, who has been appointed as the NIHR national specialty lead for rare cancers, and that will provide dedicated leadership.

More from Baroness Merron (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.